Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Qin, Wenyi ^a   Gui, Gerald ^b   Zhang, Ke ^a   Twelves, Dominique ^b   Kliethermes, Beth ^a   Sauter, Edward R ^a,c  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

Biomarkers; Breast cancer; Cancer prediction; Premalignant lesions

Indexed keywords

GLYCOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THOMSEN FRIEDENREICH ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE; CARBOHYDRATE;

ADULT; AGE; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DISCHARGE; BREAST HYPERPLASIA; CANCER INVASION; CELL DAMAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; NIPPLE ASPIRATION; POSTMENOPAUSE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION; BIOPSY; BREAST; BREAST TUMOR; CHEMISTRY; MIDDLE AGED; PATHOLOGY; PRECANCER; PREMENOPAUSE; PROSPECTIVE STUDY;

ADULT; AGED; BIOPSY; BREAST; BREAST NEOPLASMS; CARBOHYDRATES; FEMALE; HUMANS; MIDDLE AGED; NIPPLE ASPIRATE FLUID; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84856405871     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-52     Document Type: Article

References (15)

1. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002, 48(8):1194-1197.
2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72(1):1-22. 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z, 9212216.
3. Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001, 114(Pt 18):3387-3396.
4. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999, 82(2):298-304.
5. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4(8):923-928. 10.1038/nm0898-923, 9701244.
6. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001, 152(4):777-784. 10.1083/jcb.152.4.777, 2195770, 11266468.
7. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94(2):116-128. 10.1093/jnci/94.2.116, 11792750.
8. Qin W, Zhu W, Wagner-Mann C, Folk W, Sauter ER. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer. Cancer J 2003, 9(4):293-301. 10.1097/00130404-200307000-00012, 12967140.
9. Deutscher SL, Dickerson M, Gui G, Newton J, Holm JE, Vogeltanz-Holm N, Kliethermes B, Hewett JE, Kumar SR, Quinn TP, et al. Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer 2010, 10(1):519. 10.1186/1471-2407-10-519, 2958935, 20920311.
10. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984, 224(4654):1198-1206. 10.1126/science.6729450, 6729450.
11. Sauter ER, Ross E, Daly M, Klein-Szanto A, Engstrom PF, Sorling A, Malick J, Ehya H. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997, 76(4):494-501. 10.1038/bjc.1997.415, 2228000, 9275027.
12. Petrakis NL, Lim ML, Miike R, Lee RE, Morris M, Lee L, Mason L. Nipple aspirate fluids in adult nonlactating women-lactose content, cationic Na+, K+, Na+/K+ ratio, and coloration. Breast Cancer Res Treat 1989, 13(1):71-78. 10.1007/BF01806552, 2706328.
13. Huang Y, Anderson KE, Nagamani M, Grady JJ, Lu LJ. Dietary intake of lactose as a strong predictor for secretor status of nipple aspirate fluid in healthy premenopausal nonlactating women. Clin Cancer Res 2008, 14(5):1386-1392. 10.1158/1078-0432.CCR-07-4077, 2690957, 18316559.
14. Chagpar A, Evelegh M, Fritsche HA, Krishnamurthy S, Hunt KK, Kuerer HM. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. Cancer 2004, 100(12):2549-2554. 10.1002/cncr.20311, 15197795.
15. Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detect Prev 2007, 31(1):50-58. 10.1016/j.cdp.2006.12.004, 1865519, 17317033.